Toddler's Aggressive Liver Cancer Vanishes After Just Two Doses of Engineered Cell Therapy

A Case That Stunned Even the Doctors

By the time he was three years old, the boy had already endured more than most cancer patients face in a lifetime. When first diagnosed, he had a mass in the left lobe of his liver measuring 11.2 cm by 9.6 cm by 7.1 cm — nearly the size of a baseball. The cancer had metastasized to his lungs, with indications that it had also spread to his bones. Then, against all odds, it disappeared entirely — and stayed gone.

A new report published in the New England Journal of Medicine by researchers at Texas Children's, Baylor College of Medicine, and Seattle Children's describes a complete regression of hepatoblastoma, the most common pediatric liver cancer, in the 3-year-old treated with a novel immunotherapy. The findings, published on September 10, 2026, have sent ripples of excitement through the oncology world — not just for what they mean for one child, but for what they could mean for countless others.

When Chemotherapy Failed, Science Stepped In

Before enrollment in the CARE study, the patient was treated with three lines of chemotherapy and underwent complete resection of the primary liver tumor and two lung metastases. His cancer was no longer responsive to chemotherapy, and a new lung metastasis recurred after surgery. He had, in the clinical sense, run out of conventional options.

After the rapid recurrence, the boy was enrolled in the CARE study — the first human trial of an experimental form of CAR T cell therapy. CAR T cell therapy is an immunotherapy technique that involves taking a patient's immune cells and genetically engineering them to become potent cancer-hunting predators. The boy received two doses of the experimental GPC3-CAR treatment, made from his own T cells, but engineered to recognize glypican-3 (GPC3), a protein that is highly expressed in liver cancers.

The researchers also engineered the therapy to include genes that would express the immune proteins interleukin-15 and interleukin-21, to boost the CAR T cells' longevity and tumor-killing ability, based on previous evidence from preclinical models. The patient received two infusions eight weeks apart in an outpatient setting — no hospital stays, no intensive care unit, no debilitating side effects.

Two Doses. Zero Cancer.

After the first infusion, the patient showed a partial response, indicated by CT scans and falling levels of a protein called alpha-fetoprotein in his blood, which is indicative of tumor activity. Then came the second dose. Eight weeks later, he received a second dose of the therapy, and follow-up scans showed no remaining signs of the disease, apart from some residual scarring. After 12 months, the boy was still disease-free.

According to first author Dr. David Steffin, associate chief of cellular therapy and bone marrow transplant at Texas Children's, "This case demonstrates that a durable complete response in a chemotherapy-resistant solid tumor can be achieved entirely in the outpatient setting without systemic toxicity." That last part matters enormously. Traditional cancer treatments often leave patients ravaged by side effects. The child achieved complete radiographic regression after two outpatient infusions, and no cytokine release syndrome or dose-limiting toxicities occurred — with remission persisting for one year.

A Breakthrough That Could Reach Far Beyond One Child

CAR T cell therapy has shown huge promise in helping patients treat cancer, although its effectiveness has mostly been limited to treating blood cancers, not solid tumors. That's what makes this case so significant. Solid tumors — the kind that form in organs like the liver, lungs, and brain — have long been the stubborn frontier that immunotherapy struggled to crack. This result suggests that frontier may be starting to give way.

Co-author and pediatric oncologist Dr. Andras Heczey noted that "this study provides evidence that these novel CAR T cells may be a safe and effective modality for hepatoblastoma and highlights the need for further assessment in patients with GPC3+ solid tumors." In other words, the therapy's potential doesn't stop at liver cancer. Glypican-3 is expressed across a range of solid tumors, meaning the same approach could one day be tested against other cancers that have historically been among the hardest to treat. For families facing a diagnosis that once felt like a dead end, that possibility is everything.